leisure time -WSS

leisure time

author：leisure time 2025-08-12 06:43:23 - browse：82

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Covid vaccines: Private market messier than government rollout

WSS

Medicaid, Medicare dual

First transplant of an entire human eye performed

Medicare’s new pay boost for primary care is angering specialists

Weight loss drugs should be covered by insurers, AMA says

Ohio still needs to do more to protect the right to abortion

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Publishing genetic code of viruses could cause disaster

Bright Health sells Medicare Advantage business to Molina

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Kaiser Permanente unions announce official strike date

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sudafed saga points to U.S. issues with evaluating older drugs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Paxlovid should be available without a positive Covid test

knowledge

Covid vaccines: Private market messier than government rollout

Cancer diagnosis changes perspective doctor, former hospital CEO

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Would Medicare drug price negotiations stall in a shutdown?

Listen: Who gets the credit for GLP

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

entertainment

Wikipedia

entertainment

hotspot